stockrowGSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
Follow GSK
Alert me
GSK PLC Sponsored ADR (GSK) EPS (diluted)
GSK PLC Sponsored ADR's EPS (diluted) for fiscal 2025 was $3.72, up 134.0% from $1.59 in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.98. Over the past ten years it has ranged from $0.63 (fiscal 2016) to $9.19 (fiscal 2022); the current reading is higher than 82% of that period. GSK PLC Sponsored ADR ranks 9th of 20 Drug Manufacturers General companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $3.72 | 133.96% |
| FY2024 | $1.59 | (46.64%) |
| FY2023 | $2.98 | (67.57%) |
| FY2022 | $9.19 | 205.06% |
| FY2021 | $3.01 | (18.86%) |
| FY2020 | $3.71 | 23.75% |
| FY2019 | $3.00 | 23.08% |
| FY2018 | $2.44 | 140.74% |
| FY2017 | $1.01 | 62.00% |
| FY2016 | $0.63 | (90.51%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $1.12 | 287.83% |
| Jun 2026 | $0.29 | (74.74%) |
| Mar 2026 | $1.15 | 173.33% |
| Dec 2025 | $0.42 | (68.66%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AMGN Amgen Inc. compare | $17.24 |
| AZN AstraZeneca PLC compare | $7.06 |
| BMY Bristol Myers Squibb Company compare | $4.51 |
| NVO Novo Nordisk A/S compare | $4.09 |
| GSK GSK PLC Sponsored ADR | $2.98 |
| BIIB Biogen Inc. compare | $2.34 |
| SNY Sanofi compare | $2.02 |
| PFE Pfizer Inc. compare | $0.71 |
| GILD Gilead Sciences, Inc. compare | −$3.16 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on GSK
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement